sysmex | Together for a better healthcare journey

Myeloid malignancy in focus

SureSeq™ NGS panels



The SureSeq™ NGS portfolio is growing! Check out two new panels that complement the next-generation sequencing solutions for haematological cancers.

Ultra-high sensitivity
Optimised with guideline-led [1] content for myeloid MRD detection down to 0.01% VAF.

Partner gene-agnostic
Enabling simultaneous detection of multiple breakpoints and fusions within a single assay.

SureSeq

Enhanced detection of complex structural variants
SNVs, indels, ITDs, PTDs, CNVs, LOH and translocations.

Interpret NGS Analysis Software
Complimentary* use of our highly configurable and powerful software. Enables visualisation of SNVs, indels and ITDs MRD dynamics over time. Locally installed or on the cloud.

* subject to fair use

SureSeq™ Myeloid Fusion Panel - Partner gene-agnostic fusion detection

- **RNA-based, partner gene-agnostic panel:** Detects 30 common myeloid fusions plus novel fusion partners in a single cost-efficient assay, including *KMT2A* and *MECOM*.
- **Developed in partnership with myeloid cancer experts in adherence with the latest WHO guidance [2]:** Combines expert-led panel design with hybridisation-based enrichment for unparalleled uniformity and depth of coverage.

SureSeq™ Myeloid MRD Plus Panel - Measurable residual disease of myeloid samples down to 0.01% VAF

- **Ultra-high sensitivity:** Designed to confidently detect ultra-low frequency variants as low as 0.01% VAF, including key AML MRD targets such as *NPM1*.
- **Guideline-driven gene content:** Interrogate 16 key AML-associated genes including longer, ultra-low frequency *FLT3*-ITDs over 300bp long, for a clear and accurate picture of MRD status in AML samples — including MDS and MPN implicated genes.

Investigator's feedback

"Overall, we were very happy with the promising results we obtained using the SureSeq™ Myeloid MRD Panel, which has led us to implement this panel for MRD analysis in our ongoing and planned clinical trials. In our hands this panel was able to detect all variants found by a comparator NGS Panel, generating no false positive calls, and most importantly, several additional clinically relevant variants, including *FLT3*-ITDs, that had not been detected by the comparator were found".

Prof Dr Klaus Metzeler
Attending Physician, Head of Diagnostics & Translational Research
Dept. of Haematology, Cell Therapy, Haemostaseology & Infectious Diseases
University of Leipzig Medical Center, Germany

References

[1] Heuser *et al.* Blood 2021; 138(26): 2753–2767
[2] Khoury *et al.* Leukemia. 2022 ; 36:1703-19.

Consult your Sysmex representative and inquire about other SureSeq™ haematological malignancy NGS panels – **SureSeq™ Core MPN Panel, SureSeq™ Pan-Myeloid Panel, SureSeq™ Myeloid Plus Panel, and SureSeq™ CLL + CNV V3 Panel**

SureSeq™ For Research Use Only; Not for Use in Diagnostic Procedures.

Distributor EMEA: Sysmex Europe SE · www.sysmex-europe.com
Manufacturer SureSeq™: OGT · www.ogt.com
You will find your local Sysmex representative's address under www.sysmex-europe.com/contacts

www.sysmex-europe.com/sureseq

EN.C.06/26